These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29734209)

  • 1. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
    Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
    Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
    Oehler C; von Bueren AO; Furmanova P; Broggini-Tenzer A; Orlowski K; Rutkowski S; Frei K; Grotzer MA; Pruschy M
    Neuro Oncol; 2011 Sep; 13(9):1000-10. PubMed ID: 21743064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
    O'Reilly T; Wartmann M; Maira SM; Hattenberger M; Vaxelaire J; Muller M; Ferretti S; Buchdunger E; Altmann KH; McSheehy PMJ
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):307-317. PubMed ID: 15723258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.
    Laborde L; Oz F; Ristov M; Guthy D; Sterker D; McSheehy P
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):869-878. PubMed ID: 28779265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
    Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of epothilone B (patupilone) in refractory lymphoma and advanced solid tumors in dogs.
    Meier V; Geigy C; Grosse N; McSheehy P; Rohrer Bley C
    J Vet Intern Med; 2013; 27(1):120-5. PubMed ID: 23205945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.
    Melichar B; Casado E; Bridgewater J; Bennouna J; Campone M; Vitek P; Delord JP; Cerman J; Salazar R; Dvorak J; Sguotti C; Urban P; Viraswami-Appanna K; Tan E; Tabernero J
    Br J Cancer; 2011 Nov; 105(11):1646-53. PubMed ID: 22027708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
    O'Reilly T; McSheehy PM; Wenger F; Hattenberger M; Muller M; Vaxelaire J; Altmann KH; Wartmann M
    Prostate; 2005 Nov; 65(3):231-40. PubMed ID: 15948135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial.
    Tsimberidou AM; Takimoto CH; Moulder S; Uehara C; Mita M; Mita A; Urban P; Tan E; Wang Y; Vining D; Kurzrock R
    Mol Cancer Ther; 2011 Jan; 10(1):209-17. PubMed ID: 21220503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of patupilone in patients with advanced solid tumor malignancies.
    Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
    Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.
    Nayak L; DeAngelis LM; Robins HI; Govindan R; Gadgeel S; Kelly K; Rigas JR; Peereboom DM; Rosenfeld SS; Muzikansky A; Zheng M; Urban P; Abrey LE; Omuro A; Wen PY
    Cancer; 2015 Dec; 121(23):4165-72. PubMed ID: 26308485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
    Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.
    Ferretti S; Allegrini PR; O'Reilly T; Schnell C; Stumm M; Wartmann M; Wood J; McSheehy PM
    Clin Cancer Res; 2005 Nov; 11(21):7773-84. PubMed ID: 16278399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
    Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
    Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
    Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the microenvironment for radiosensitization by patupilone.
    Bley CR; Jochum W; Orlowski K; Furmanova P; Vuong V; McSheehy PM; Pruschy M
    Clin Cancer Res; 2009 Feb; 15(4):1335-42. PubMed ID: 19228735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
    BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.